Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Authors
Tymon-Rosario, Joan R.Manara, PaolaManavella, Diego D.Bellone, StefaniaHartwich, Tobias Max PhilippHarold, JustinYang-Hartwich, YangZipponi, MargheritaChoi, JungminJeong, KyungjoMutlu, LeventYang, KevinAltwerger, GaryMenderes, GuldenRatner, ElenaHuang, Gloria S.Clark, MitchellAndikyan, VaagnAzodi, MasoudSchwartz, Peter E.Alexandrov, Ludmil B.Santin, Alessandro D.
Issue Date
7월-2022
Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
Keywords
Carcinosarcoma; Homologous-recombination-deficiency(HRD); Poly(ADP-ribose)-polymeraseinhibitors; (PARPi); Whole-exome-sequencing(WES)
Citation
GYNECOLOGIC ONCOLOGY, v.166, no.1, pp.117 - 125
Indexed
SCIE
SCOPUS
Journal Title
GYNECOLOGIC ONCOLOGY
Volume
166
Number
1
Start Page
117
End Page
125
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/143393
DOI
10.1016/j.ygyno.2022.05.005
ISSN
0090-8258
Abstract
Objectives. Carcinosarcoma (CS) of the ovary and uterus are highly aggressive malignancies associated with poor survival. Poly(ADP-ribose)-polymerase inhibitors (PARPi) are targeted agents impairing DNA repair via homologous-recombination-deficiency (HRD) mechanisms. We used whole-exome-sequencing (WES) data from a cohort of fresh tumor samples of ovarian (OCS) and uterine carcinosarcoma (UCS), primary cell lines and xenografts to investigate the role for olaparib in CSs. Methods. WES data from 73 CS samples (48 UCS and 25 OCS) were analyzed for HRD signatures. Olaparib activity was evaluated using cell-viability, cell-cycle, apoptosis and cytotoxicity assays against primary CS cell lines. Olaparib antitumor activity was tested in vivo against HRD CS xenografts. Results. Signature-3 (i.e. HRD-related signature) was identified in 60% of OCS (15 of 25) vs 25% of UCS (12 of 48) (p = 0.005). CS cell lines harboring Signature-3/HRD (3 OCS/1 UCS) were significantly more sensitive to olaparib when compared to HRP cell lines (5 UCS/1 OCS) [mean IC50 +/- SEM = 2.94 mu M +/- 0.07 vs mean +/- SEM = 23.3 mu M +/- 0.09, (p = 0.02), respectively]. PARPi suppressed CS cell growth through cell cycle arrest in the G2/M phase and caused more apoptosis in HRD vs HRP primary tumors (p < 0.0001). In vivo, olaparib significantly impaired HRD CS xenografts tumor growth (p = 0.0008) and increased overall animal survival (p < 0.0001). Conclusions. OCS and UCS cell lines harboring HRD signature-3 were significantly more sensitive to olaparib in vitro and in vivo when compared to HRP CS. Clinical studies with PARPi in CS patients with a dominant signature 3 (HRD-related) are warranted.
Files in This Item
There are no files associated with this item.
Appears in
Collections
Graduate School > Department of Biomedical Sciences > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE